<unk>  is used to treat atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH). For people with PNH, it improves quality of life and decreases the need for blood transfusions but does not appear to affect the risk of death. It does not appear to change the risk of blood clots, myelodysplastic syndrome, acute myelogenous leukemia, or aplastic anemia.<unk>  is also used to treat neuromyelitis optica spectrum disorder in adults who are anti-aquaporin-4 (AQP4) antibody positive.<unk>  has also been explored as a treatment for CD55 deficiency, also known as CHAPLE syndrome, a rare genetic disorder of the immune system. With approval for compassionate off-label use, Kurolap and colleagues treated patients with the drug and found it to have positive clinical and laboratory outcomes over an 18-month period.<unk>  is administered in a doctor's office or clinic by intravenous infusion. Women should not become pregnant while taking<unk>  and pregnant women should take it only if it is clearly necessary.
Eculizumab
Brolucizumab
Emicizumab
Satralizumab
Natalizumab
Ixekizumab
Theralizumab
Tocilizumab